While Novogaia is building a next-gen discovery platform, CEO Tess Bevers emphasizes that the company's primary focus must be advancing its first drug candidates. For early-stage biotechs, the tangible value lies in getting molecules further down the pipeline, not just in perfecting the underlying technology.

Since most biotech programs fail (as few as 1 in 10 succeed), a company's survival depends on running a portfolio of multiple programs simultaneously. This requires the discipline to quickly terminate unsuccessful projects and the foresight to have subsequent programs already underway.

Unlike ventures in established biological pathways, startups tackling novel biology must first prove a specific drug product can work. The primary question isn't about the platform's potential applications but whether a single, tangible therapeutic is viable. Focusing on a broad platform too early is a mistake.

Experts advise platform technology founders to resist showcasing broad applicability. Instead, they should focus on specific use cases where they can generate compelling evidence, such as for a particular disease or drug modality. This builds credibility and creates a "beachhead" for future expansion.

In biotech, early data is often ambiguous. Instead of judging programs on potential, leaders must prioritize based on the time and capital required to reach a clear 'yes' or 'no' outcome. Indefinite 'gray zone' projects drain resources that could fund a winner.

Founders of platform technologies are often tempted to pursue many applications at once. A more effective strategy is to select and aggressively advance a single "beachhead program" to the clinic. This demonstrates the platform's value concretely, making it easier to attract funding and partners, while avoiding the dilution of resources.

For a platform company with wide-ranging technology, the key early struggle is focusing. It is critical to prioritize a single program to generate near-term data and change the cost of capital before realizing the platform's full potential.

The lead asset overwhelmingly determines a biotech company's value at IPO or acquisition, with subsequent programs and the platform contributing far less. This means founders must prioritize their most impactful idea as their first program, not a cheaper proof-of-concept, to maximize value creation.

The venture creation strategy for platform biotechs isn't about finding one blockbuster drug. It's a binary bet: either the underlying scientific platform is sound and can repeatedly generate many medicines, or the entire concept fails. There is no middle ground of succeeding with just one product from the platform.